Exelixis Patent-Cliff Exposure & CMS Drug Spending Portfolio

Exelixis (Alameda, CA): 2 reconciled FDA prescription therapies (99.7% 2025 to 2030 cliff risk), $1.35B 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterAlameda, CA
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure99.7%
Primary Portfolio LOE Date2032-01-01
2024 CMS Total Public Spend$1.35B
2024 Medicare Part D Spend$1.22B
2024 Medicaid Spend$129.4M
California HCAI SB 17 Filings3 WAC filings (max 18.1% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Exelixis across sibling Meru public-data platforms.